FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Publications
  • Links
  • News
✕
Published by Austin on March 7, 2022
Categories

Augenklinik, Forschergruppe FOR 2240

  • DateMarch 7, 2022
  • Executive Board
  • Research Groups
  • Central Projects
  • Associated projects
  • Alumni

Curriculum Vitae

Volkan Tahmaz

Department of Ophthalmology
University of Cologne
Kerpener Straße 62
50937 Cologne, Germany
Email: volkan.tahmaz@uk-koeln.de

Scientific career

2017-Affiliated Clinician-Scientist at the PhD student level in Project 1 “Induction of transplant tolerance by antihem- and antilymphangiogenic therapies” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Ophthalmology, University of Cologne

2018- Affiliated Clinician-Scientist at the PhD student level in Project P1 “Induction of corneal transplant tolerance by anti(lymph)angiogenic therapy” in the DFG Research Unit FOR 2240 “Angiogenesis, Lymphangiogenesis and Cellular Immunity in Inflammatory Diseases of the Eye” at the Department of Ophthalmology, University of Cologne

Selected publications

Tahmaz V, Gehlsen U, Sauerbier L, Holtick U, Engel L, Radojska S, Petrescu-Jipa VM, Scheid C, Hallek M, Gathof B, Cursiefen C, Steven P. Treatment  of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. Br J  Ophthalmol. 2016 Jun 6. pii: bjophthalmol-2015-307666.

Steven P, Sauerbier L, Siebelmann S, Gehlsen U, Tahmaz V, Wittig S, Scheid C, Cursiefen C. [Therapy for Ocular Graft-vs-Host Disease]. Klin Monbl Augenheilkd. 2015 May;232(5):658-63.

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Claudia Bock
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
claudia.bock@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck
      Um unsere Website für Sie optimal zu gestalten und fortlaufend verbessern zu können, verwenden wir Cookies. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen zu Cookies und insb. der Möglichkeiten, der Verwendung von Cookies zu widersprechen, erhalten Sie in unserer Datenschutzerklärung.SchließenDatenschutzerklärung